This includes COL1A1 and COL1A2 (coding for Collagen Type I), COL3A1 (Collagen Type III), and ELN (Elastin)
Why the brand-name trumps all To that end, when there arent any insurance or financial pressures steering the decision, Phoenix and Raven generally recommend brand-name Ozempic as the first-line option as Broussenko believes it has a long track record, a robust supply chain, and a level of familiarity that removes guesswork for both patients and providers
Mounjaro insurance coverage often supports diabetes rather than weight loss applications, guiding patients towards Zepbound or similar options for treating weight issues
Men with high visceral fat, obesity, or metabolic syndrome may benefit most
Advertisement Advertisement Inclusion of genomic profiling and risk factors recommended for treatment planning Large retrospective analysis may prompt prospective studies Robust signal from observational study raises prospect of a long-sought medical therapy Post hoc analysis of SURPASS-CVOT trial has implications for future cardiovascular outcome trials Retrospective analysis finds lower mortality rates, fewer hospital visits among patients with Type 1 diabetes using GLP-1 Therapies Observational evidence of neuroprotection with GLP-1 receptor agonists and SGLT-2 inhibitors Study is first to show reduction in autoimmune disease with the common diabetes and obesity drugs Surgical intervention linked to increased lifespan and reduced complications